Search

Your search keyword '"Parolini, O"' showing total 18 results
Start Over Author "Parolini, O" Publisher elsevier b.v.
18 results on '"Parolini, O"'

1. Slow and steady wins the race: Fractionated near-infrared treatment empowered by graphene-enhanced 3D scaffolds for precision oncology

Author

Perini, Giordano, Palmieri, V., Papait, Andrea, Augello, A., Fioretti, D., Iurescia, S., Rinaldi, M., Vertua, E., Silini, Antonietta Rosa, Torelli, R., Carlino, Anastasia, Musarra, T., Sanguinetti, Maurizio, Parolini, Ornella, De Spirito, Marco, Papi, Massimiliano, Perini G. (ORCID:0000-0001-9452-8479), Papait A. (ORCID:0000-0003-1229-9671), Silini A., Carlino A., Sanguinetti M. (ORCID:0000-0002-9780-7059), Parolini O. (ORCID:0000-0002-5211-6430), De Spirito M. (ORCID:0000-0003-4260-5107), Papi M. (ORCID:0000-0002-0029-1309), Perini, Giordano, Palmieri, V., Papait, Andrea, Augello, A., Fioretti, D., Iurescia, S., Rinaldi, M., Vertua, E., Silini, Antonietta Rosa, Torelli, R., Carlino, Anastasia, Musarra, T., Sanguinetti, Maurizio, Parolini, Ornella, De Spirito, Marco, Papi, Massimiliano, Perini G. (ORCID:0000-0001-9452-8479), Papait A. (ORCID:0000-0003-1229-9671), Silini A., Carlino A., Sanguinetti M. (ORCID:0000-0002-9780-7059), Parolini O. (ORCID:0000-0002-5211-6430), De Spirito M. (ORCID:0000-0003-4260-5107), and Papi M. (ORCID:0000-0002-0029-1309)

Abstract

Surgically addressing tumors poses a challenge, requiring a tailored, multidisciplinary approach for each patient based on the unique aspects of their case. Innovative therapeutic regimens combined to reliable reconstructive methods can contribute to an extended patient's life expectancy. This study presents a detailed comparative investigation of near-infrared therapy protocols, examining the impact of non-fractionated and fractionated irradiation regimens on cancer treatment. The therapy is based on the implantation of graphene oxide/poly(lactic-co-glycolic acid) three-dimensional printed scaffolds, exploring their versatile applications in oncology by the examination of pro-inflammatory cytokine secretion, immune response, and in vitro and in vivo tumor therapy. The investigation into cell death patterns (apoptosis vs necrosis) underlines the pivotal role of protocol selection underscores the critical influence of treatment duration on cell fate, establishing a crucial parameter in therapeutic decision-making. In vivo experiments corroborated the profound impact of protocol selection on tumor response. The fractionated regimen emerged as the standout performer, achieving a substantial reduction in tumor size over time, surpassing the efficacy of the non-fractionated approach. Additionally, the fractionated regimen exhibited efficacy also in targeting tumors in proximity but not in direct contact to the scaffolds. Our results address a critical gap in current research, highlighting the absence of a standardized protocol for optimizing the outcome of photodynamic therapy. The findings underscore the importance of personalized treatment strategies in achieving optimal therapeutic efficacy for precision cancer therapy.

Published
2024

2. Biosynthesis and physico-chemical characterization of high performing peptide hydrogels@graphene oxide composites

Author

Chronopoulou, L., Di Nitto, A., Papi, Massimiliano, Parolini, Ornella, Falconi, M., Teti, G., Muttini, A., Lattanzi, Wanda, Palmieri, Valentina, Ciasca, Gabriele, Del Giudice, A., Galantini, L., Zanoni, R., Palocci, C., Papi M. (ORCID:0000-0002-0029-1309), Parolini O. (ORCID:0000-0002-5211-6430), Lattanzi W. (ORCID:0000-0003-3092-4936), Palmieri V., Ciasca G. (ORCID:0000-0002-3694-8229), Chronopoulou, L., Di Nitto, A., Papi, Massimiliano, Parolini, Ornella, Falconi, M., Teti, G., Muttini, A., Lattanzi, Wanda, Palmieri, Valentina, Ciasca, Gabriele, Del Giudice, A., Galantini, L., Zanoni, R., Palocci, C., Papi M. (ORCID:0000-0002-0029-1309), Parolini O. (ORCID:0000-0002-5211-6430), Lattanzi W. (ORCID:0000-0003-3092-4936), Palmieri V., and Ciasca G. (ORCID:0000-0002-3694-8229)

Abstract

Hydrogels based on short peptide molecules are interesting biomaterials with wide present and prospective use in biotechnologies. A well-known possible drawback of these materials can be their limited mechanical performance. In order to overcome this problem, we prepared Fmoc-Phe3self-assembling peptides by a biocatalytic approach, and we reinforced the hydrogel with graphene oxide nanosheets. The formulation here proposed confers to the hydrogel additional physicochemical properties without hampering peptide self-assembly. We investigated in depth the effect of nanocarbon morphology on hydrogel properties (i.e. morphology, viscoelastic properties, stiffness, resistance to an applied stress). In view of further developments towards possible clinical applications, we have preliminarily tested the biocompatibility of the composites. Our results showed that the innovative hydrogel composite formulation based on FmocPhe3 and GO is a biomaterial with improved mechanical properties that appears suitable for the development of biotechnological applications.

Published
2021

4. Review: Preclinical studies on placenta-derived cells and amniotic membrane: An update.

Author

Parolini, O. and Caruso, M.

Subjects
AMNION, PLACENTA, STEM cell treatment, ANIMAL disease models, INFLAMMATION, HEALTH outcome assessment
Abstract

Abstract: Recent years have seen considerable advances in our knowledge of the biology and properties of stem/progenitor cells isolated from placental tissues. This has encouraged researchers to address the potential effects of these cells in animal models of different diseases, resulting in increasing expectations regarding their possible utility for cell-based therapeutic applications. This rapidly evolving research field is also enriched by studies aimed at expanding the use of the whole amniotic membrane (AM), a well-known surgical material, for pathological conditions other than those tested so far and for which clinical applications already exist. In this review, we provide an update on studies that have been performed with placenta-derived cells and fragments of the entire AM to validate their potential clinical applications in a variety of diseases, in particular those associated with degenerative processes induced by inflammatory and fibrotic mechanisms. We also offer, as far as possible, insight into the interpretation and suggested mechanisms to explain the most important outcomes achieved to date. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

14. Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS).

Author

Parolini, O., Alviano, F., Betz, A.G., Bianchi, D.W., Götherström, C., Manuelpillai, U., Mellor, A.L., Ofir, R., Ponsaerts, P., Scherjon, S.A., Weiss, M.L., Wolbank, S., Wood, K.J., and Borlongan, C.V.

Subjects
STEM cells, PLACENTA, FETAL membranes, BIOLOGICAL societies, MEETINGS, LECTURES & lecturing, IMMUNOREGULATION, MESENCHYMAL stem cells
Abstract

Abstract: The International Placenta Stem Cell Society (IPLASS) was founded in June 2010. Its goal is to serve as a network for advancing research and clinical applications of stem/progenitor cells isolated from human term placental tissues, including the amnio-chorionic fetal membranes and Wharton’s jelly. The commitment of the Society to champion placenta as a stem cell source was realized with the inaugural meeting of IPLASS held in Brescia, Italy, in October 2010. Officially designated as an EMBO-endorsed scientific activity, international experts in the field gathered for a 3-day meeting, which commenced with “Meet with the experts” sessions, IPLASS member and board meetings, and welcome remarks by Dr. Ornella Parolini, President of IPLASS. The evening’s highlight was a keynote plenary lecture by Dr. Diana Bianchi. The subsequent scientific program consisted of morning and afternoon oral and poster presentations, followed by social events. Both provided many opportunities for intellectual exchange among the 120 multi-national participants. This allowed a methodical and deliberate evaluation of the status of placental cells in research in regenerative and reparative medicine. The meeting concluded with Dr. Parolini summarizing the meeting’s highlights. This further prepared the fertile ground on which to build the promising potential of placental cell research. The second IPLASS meeting will take place in September 2012 in Vienna, Austria. This meeting report summarizes the thought-provoking lectures delivered at the first meeting of IPLASS. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

18. Amniotic membrane and amniotic cells: Potential therapeutic tools to combat tissue inflammation and fibrosis?

Author

Manuelpillai, U., Moodley, Y., Borlongan, C.V., and Parolini, O.

Subjects
CELL membranes, AMNIOTIC liquid, UMBILICAL cord, PLACENTA, THERAPEUTICS, INFLAMMATION, FIBROSIS, MESENCHYMAL stem cells
Abstract

Abstract: In addition to the placenta, umbilical cord and amniotic fluid, the amniotic membrane is emerging as an immensely valuable and easily accessible source of stem and progenitor cells. This concise review will focus on the stem/progenitor cell properties of human amniotic epithelial and mesenchymal stromal cells and evaluate the effects exerted by these cells and the amniotic membrane on tissue inflammation and fibrosis. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results